Shuang Li

Shuang Li is a seasoned professional in analytical development and chemistry, currently serving as the Senior Director of Analytical Development CMC at ReCode Therapeutics since 2021. Prior to this position, Shuang Li held various leadership roles at Genentech from 2017 to 2021, including Head of Analytical Chemistry in Global Analytical Science and Technology. Experience also includes serving as a Research Scientist II at Gilead Sciences and a Principal Scientist in Analytical Development at Relypsa. Earlier roles encompassed Product Analytical Group Leader at Teva Pharmaceuticals, Senior Scientist at Watson Pharmaceuticals, and Research Scientist/Group Leader at PPD.